[go: up one dir, main page]

WO2002068476A3 - Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders - Google Patents

Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders Download PDF

Info

Publication number
WO2002068476A3
WO2002068476A3 PCT/US2002/005684 US0205684W WO02068476A3 WO 2002068476 A3 WO2002068476 A3 WO 2002068476A3 US 0205684 W US0205684 W US 0205684W WO 02068476 A3 WO02068476 A3 WO 02068476A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
inflammatory disorders
treating inflammatory
composition
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/005684
Other languages
French (fr)
Other versions
WO2002068476A2 (en
Inventor
Kenneth Jacobs
Debra Pittman
Lynette Fouser
Vikki Spaulding
Dejun Xuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2002252097A priority Critical patent/AU2002252097A2/en
Priority to MXPA03007413A priority patent/MXPA03007413A/en
Priority to NZ527396A priority patent/NZ527396A/en
Priority to EP02721152A priority patent/EP1373319A2/en
Priority to BR0207528-8A priority patent/BR0207528A/en
Priority to CA002438238A priority patent/CA2438238A1/en
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Priority to JP2002567986A priority patent/JP2005510451A/en
Publication of WO2002068476A2 publication Critical patent/WO2002068476A2/en
Priority to ZA2003/06071A priority patent/ZA200306071B/en
Publication of WO2002068476A3 publication Critical patent/WO2002068476A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)

Abstract

Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.
PCT/US2002/005684 2001-02-23 2002-02-25 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders Ceased WO2002068476A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MXPA03007413A MXPA03007413A (en) 2001-02-23 2002-02-25 Composition and method for treating inflammatory disorders.
NZ527396A NZ527396A (en) 2001-02-23 2002-02-25 Antibodies and fragments thereof for the binding of IL-22 and use therefore for treating inflammatory disorders
EP02721152A EP1373319A2 (en) 2001-02-23 2002-02-25 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
BR0207528-8A BR0207528A (en) 2001-02-23 2002-02-25 Antibody, pharmaceutical composition, and uses of an effective amount of an agent, a therapeutically effective amount of an il-22 antibody, an immunogenic amount of antigen, and an immunogenicity enhancing amount of il-22 in combination, a effective amount of the antibody or fragment thereof and a sufficient amount of antibody or antigen-linked fragment thereof
CA002438238A CA2438238A1 (en) 2001-02-23 2002-02-25 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
AU2002252097A AU2002252097A2 (en) 2001-02-23 2002-02-25 Composition and method for treating inflammatory disorders
JP2002567986A JP2005510451A (en) 2001-02-23 2002-02-25 Compositions and methods for treating inflammatory disorders
ZA2003/06071A ZA200306071B (en) 2001-02-23 2003-08-06 Composition and method for treating inflammatory disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27082301P 2001-02-23 2001-02-23
US60/270,823 2001-02-23
US28135301P 2001-04-03 2001-04-03
US60/281,353 2001-04-03

Publications (2)

Publication Number Publication Date
WO2002068476A2 WO2002068476A2 (en) 2002-09-06
WO2002068476A3 true WO2002068476A3 (en) 2003-08-07

Family

ID=26954516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/005684 Ceased WO2002068476A2 (en) 2001-02-23 2002-02-25 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders

Country Status (9)

Country Link
EP (1) EP1373319A2 (en)
JP (2) JP2005510451A (en)
AU (2) AU2002252097A2 (en)
BR (1) BR0207528A (en)
CA (1) CA2438238A1 (en)
MX (1) MXPA03007413A (en)
NZ (1) NZ527396A (en)
WO (1) WO2002068476A2 (en)
ZA (1) ZA200306071B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9815880B2 (en) 2013-03-15 2017-11-14 Genentech, Inc. IL-22 Fc fusion proteins

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
WO2002012345A2 (en) 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
CA2438238A1 (en) * 2001-02-23 2002-09-06 Genetics Institute, Llc. Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
US7638604B2 (en) 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
AU2003223344B9 (en) 2002-03-22 2009-07-16 Zymogenetics, Inc. Anti-IL-TIF antibodies and methods of using in inflammation
KR20110091598A (en) 2003-03-24 2011-08-11 지모제넥틱스, 인코포레이티드 Anti-IL-22RA antibodies and binding partners and methods of use in inflammation
DE602004030341D1 (en) * 2003-06-23 2011-01-13 Genetics Inst Llc ANTIBODIES TO INTERLEUKIN-22 AND USES THEREOF
BRPI0516975A (en) 2004-10-22 2008-09-30 Zymogenetics Inc antibody or antigen-binding fragment thereof, pharmaceutical composition, immunoconjugate, hybridoma, monoclonal antibody, and use of an antibody or antigen-binding fragment thereof
JP2008532931A (en) 2005-02-08 2008-08-21 ザイモジェネティクス， インコーポレイテッド Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and uses in inflammation
EP3006466B1 (en) * 2005-12-02 2018-08-01 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
TW200744634A (en) * 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (en) 2006-02-21 2013-12-01 Wyeth Corp Antibodies against human il-22 and uses therefor
JP7473977B2 (en) 2018-06-05 2024-04-24 バイオアトラ インコーポレイテッド Anti-IL22 antibodies, antibody fragments and immunoconjugates thereof and uses thereof
WO2023110942A1 (en) * 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4208799A (en) * 1998-05-29 1999-12-13 Human Genome Sciences, Inc. Interleukins-21 and 22
JP3769189B2 (en) * 1998-10-26 2006-04-19 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Isolated nucleic acid molecule encoding T cell inducible factor (TIF), encoded protein and uses thereof
NZ515678A (en) * 1999-04-28 2004-01-30 Genetics Inst Human GIL-19/AE289 proteins and polynucleotides encoding same
AU2292601A (en) * 1999-12-23 2001-07-03 Zymogenetics Inc. Novel cytokine zcyto18
CA2438238A1 (en) * 2001-02-23 2002-09-06 Genetics Institute, Llc. Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DUMOUTIER L ET AL: "CLONING AND CHARACTERIZATION OF IL-10-RELATED T CELL-DERIVED INDUCIBLE FACTOR (IL-TIF), A NOVEL CYTOKINE STRUCTURALLY RELATED TO IL-10 AND INDUCIBLE BY IL-9", JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, GB, vol. 164, 2000, pages 1814 - 1819, XP000946156, ISSN: 0019-2805 *
DUMOUTIER L ET AL: "HUMAN INTERLEUKIN-10-RELATED T CELL-DERIVED INDUCIBLE FACTOR: MOLECULAR CLONING AND FUNCTIONAL CHARACTERIZATION AS AN HEPATOCYTE-STIMULATING FACTOR", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 18, 29 August 2000 (2000-08-29), pages 10144 - 10149, XP000946025, ISSN: 0027-8424 *
DUMOUTIER L ET AL: "IL-TIF induces acute phase reactant production by hepatocytes through IL-10Rbeta.", IMMUNOLOGY LETTERS, vol. 73, no. 2-3, September 2000 (2000-09-01), 24th European Immunology Meeting of the European Federation of Immunological Societies;Poznan, Poland; September 23-26, 2000, pages 261, XP009012155, ISSN: 0165-2478 *
KOTENKO SERGEI V ET AL: "Identification of the functional interleukin-22 (IL-22) receptor complex. The IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 4, 26 January 2001 (2001-01-26), pages 2725 - 2732, XP002186669, ISSN: 0021-9258 *
LAMBERT A ET AL: "Novel cytokine IL-22 administrated by adenovirus vector or as recombinant purified protein induces acute-phase responses and renal tubular basophilia in female C57BL/6 mice.", TOXICOLOGIC PATHOLOGY, vol. 29, no. 6, November 2001 (2001-11-01), Sixteenth Aspen Cancer Conference on Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention, and Cancer Therapy;Aspen, Colorado, USA; July 15-18, 2001, pages 712, XP009012154, ISSN: 0192-6233 *
XIE M-H ET AL: "Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 40, 6 October 2000 (2000-10-06), pages 31335 - 31339, XP002164307, ISSN: 0021-9258 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9815880B2 (en) 2013-03-15 2017-11-14 Genentech, Inc. IL-22 Fc fusion proteins
US10087227B2 (en) 2013-03-15 2018-10-02 Genentech, Inc. Nucleic acids encoding IL-22 Fc fusion proteins
US10160793B2 (en) 2013-03-15 2018-12-25 Genentech, Inc. Methods of treating inflammatory bowel disease using IL-22 Fc fusion proteins
US10544198B2 (en) 2013-03-15 2020-01-28 Genentech, Inc. Methods of accelerating or improving wound healing using IL-22 FC fusion proteins
US10584155B2 (en) 2013-03-15 2020-03-10 Genentech, Inc. Pharmaceutical compositions of IL-22 Fc fusion proteins
US11130791B2 (en) 2013-03-15 2021-09-28 Genentech, Inc. Methods for treating metabolic syndrome using IL-22 Fc fusion proteins
US11136365B2 (en) 2013-03-15 2021-10-05 Genentech, Inc. Methods for preventing or treating cardiovascular conditions using il-22 fc fusion proteins
US11155591B2 (en) 2013-03-15 2021-10-26 Genentech, Inc. Methods of treating acute pancreatitis using IL-22 fc fusion proteins
US11332507B2 (en) 2013-03-15 2022-05-17 Genentech, Inc. IL-22 Fc fusion proteins

Also Published As

Publication number Publication date
ZA200306071B (en) 2005-11-30
WO2002068476A2 (en) 2002-09-06
AU2002252097A2 (en) 2002-09-12
EP1373319A2 (en) 2004-01-02
JP2009137986A (en) 2009-06-25
AU2008203342B8 (en) 2011-03-17
AU2008203342A1 (en) 2008-08-14
BR0207528A (en) 2006-01-17
CA2438238A1 (en) 2002-09-06
MXPA03007413A (en) 2003-11-18
AU2008203342B2 (en) 2011-02-17
NZ527396A (en) 2007-12-21
JP2005510451A (en) 2005-04-21

Similar Documents

Publication Publication Date Title
WO2004046120A3 (en) Diaminotriazoles useful as inhibitors of protein kinases
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
WO2002089738A3 (en) Proteomimetic compounds and methods
WO2003082208A3 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
AU2003213787A1 (en) Compositions and methods for the treatment of anorectal disorders
AU2003238561A1 (en) Compositions and methods for treating gynaecological disorders
WO2002068476A3 (en) Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
AUPS017702A0 (en) Methods and compositions for the treatment of asthma and related disorders
WO2004087073A3 (en) Treatment of demyelinating conditions
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2002083622A3 (en) Novel aminophenyl ketone derivatives
AU2002326745A1 (en) Compositions and methods for generating antigen-binding units
AU2002346882A1 (en) Methods for the treatment of osteoarthritis and compositions thereof
AU2002249983A1 (en) Compositions and methods for diagnosis of neuropsychiatric disorders
WO2004026892A3 (en) Fragmentation of dna
WO2005044244A3 (en) Use of mrp4-inhibitors for the treatment and/or prophylaxis of cardiovascular diseases
AU2003276844A1 (en) Formulations of modified antibodies and methods of making the same
WO2006024958A3 (en) Cannabinoid compositions and methods of use thereof

Legal Events

Date Code Title Description
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 527396

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003/06071

Country of ref document: ZA

Ref document number: 200306071

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002252097

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2438238

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/007413

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002721152

Country of ref document: EP

Ref document number: 2002567986

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002721152

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: PI0207528

Country of ref document: BR